Haynes Lab:Notebook/Synthetic Biology and Bioinformatics for Predictable Control of Therapeutic Gene2/2013/01/25: Difference between revisions
Caroline Hom (talk | contribs) |
Caroline Hom (talk | contribs) |
||
(3 intermediate revisions by the same user not shown) | |||
Line 9: | Line 9: | ||
'''K562''' | '''K562''' | ||
<br> | <br> | ||
''MAP Kinase Activity'' | |||
#MAPK1: MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M. | |||
#NLK: Common variation in Nemo-like kinase is associated with risk of ovarian cancer. | |||
''phosphotransferase activity, alcohol group as acceptor'' | ''phosphotransferase activity, alcohol group as acceptor'' | ||
Line 18: | Line 21: | ||
#PBK: PBK/TOPK (PDZ-binding kinase, T-LAK-cell-originated protein kinase) is a serine-threonine kinase that is overexpressed in a variety of tumor cells. | #PBK: PBK/TOPK (PDZ-binding kinase, T-LAK-cell-originated protein kinase) is a serine-threonine kinase that is overexpressed in a variety of tumor cells. | ||
#MAP4K1: Results indicate that uncleaved HPK1 is a positive regulator of vitamin D-induced differentiation in acute myeloid leukemia cells, but the cleaved HPK1 fragment inhibits differentiation. May function as a novel tumor suppressor and its loss plays a critical role in pancreatic cancer. | #MAP4K1: Results indicate that uncleaved HPK1 is a positive regulator of vitamin D-induced differentiation in acute myeloid leukemia cells, but the cleaved HPK1 fragment inhibits differentiation. May function as a novel tumor suppressor and its loss plays a critical role in pancreatic cancer. | ||
#RIPK2: It is a potent activator of NF-kappaB and inducer of apoptosis in response to various stimuli. | |||
#FUK: The protein encoded by this gene belongs to the GHMP (galacto-, homoserine, mevalonate and phosphomevalonate) kinase family and catalyzes the phosphorylation of L-fucose to form beta-L-fucose 1-phosphate. This enzyme catalyzes the first step in the utilization of free L-fucose in glycoprotein and glycolipid synthesis. L-fucose may be important in mediating a number of cell-cell interactions such as blood group antigen recognition, inflammation, and metastatis. | |||
#LMTK3: LMTK3 is a therapeutic target in breast cancer. | |||
#PIP5KL1: Overexpression of PIP5KL1 suppresses cell proliferation and migration in human gastric cancer cells. | |||
#PRKAA1: Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. Data suggest that macrophage migration inhibitory factor (MIF) and d-dopachrome tautomerase (d-DT) act cooperatively to inhibit steady-state phosphorylation and activation of AMPK in LKB1 wild type and LKB1 mutant non-small cell lung carcinomas cells. | |||
''Protein Kinase Activity'' | ''Protein Kinase Activity'' | ||
Line 30: | Line 38: | ||
#FGFR1OP: FGFR1 oncogene partner | #FGFR1OP: FGFR1 oncogene partner | ||
#HIPK2: The encoded protein interacts with homeodomain transcription factors and many other transcription factors such as p53. | #HIPK2: The encoded protein interacts with homeodomain transcription factors and many other transcription factors such as p53. | ||
#CSNK2B: A dysregulation of CK2beta expression might contribute to epithelial-to-mesenchymal-transition induction during cancer progression. There was a positive correlation between the expressions of CK2alpha and CK2beta in laryngeal squamous cell carcinoma. | |||
''structural molecule activity'' | ''structural molecule activity'' | ||
Line 44: | Line 52: | ||
#APOL1: Alterations in ApoL1 function due to genetic, environmental, and lifestyle factors have been associated with African sleeping sickness, atherosclerosis, lipid disorders, obesity, schizophrenia, cancer, and chronic kidney disease (CKD). Similarly, ApoL1 may protect kidney cells against renal cell carcinoma (RCC). | #APOL1: Alterations in ApoL1 function due to genetic, environmental, and lifestyle factors have been associated with African sleeping sickness, atherosclerosis, lipid disorders, obesity, schizophrenia, cancer, and chronic kidney disease (CKD). Similarly, ApoL1 may protect kidney cells against renal cell carcinoma (RCC). | ||
''protein tyrosine kinase activity'' | |||
#NRP1: Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation. High NRP1 is associated with acute myeloid and acute lymphoid leukemia. | |||
''kinase activity'' | |||
# | #PIK3C3: PI 3-kinases p110 alpha- and beta- are ubiquitously expressed whilst p110 delta- expression is associated with leukocytes. Activating mutations in the p110alpha- subunit have recently been discovered in certain types of cancer cell. | ||
<br> | <br> | ||
Line 62: | Line 62: | ||
'''SK-N-SH''' | '''SK-N-SH''' | ||
<br> | <br> | ||
''signaling receptor activity'' | ''signaling receptor activity'' | ||
#SFRP4: Secreted frizzled-related protein 4 (SFRP4) is a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins. SFRPs act as soluble modulators of Wnt signaling. (Wnt-signaling is highly involved in various cancers) | #SFRP4: Secreted frizzled-related protein 4 (SFRP4) is a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins. SFRPs act as soluble modulators of Wnt signaling. (Wnt-signaling is highly involved in various cancers) | ||
Line 82: | Line 83: | ||
#CREB3L3: This gene encodes a member of the basic-leucine zipper family and the AMP-dependent transcription factor family. The encoded protein is localized to the endoplasmic reticulum and acts as a transcription factor activated by cyclic AMP stimulation. The encoded protein binds the cyclic AMP response element (CRE) and the box-B element and has been linked to acute inflammatory response, hepatocellular carcinoma, triglyceride metabolism, and hepcidin expression. | #CREB3L3: This gene encodes a member of the basic-leucine zipper family and the AMP-dependent transcription factor family. The encoded protein is localized to the endoplasmic reticulum and acts as a transcription factor activated by cyclic AMP stimulation. The encoded protein binds the cyclic AMP response element (CRE) and the box-B element and has been linked to acute inflammatory response, hepatocellular carcinoma, triglyceride metabolism, and hepcidin expression. | ||
#RUNX3: It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. | #RUNX3: It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. | ||
''G-protein coupled receptor activity'' | ''G-protein coupled receptor activity'' | ||
Line 106: | Line 106: | ||
#TNFSF14: The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. | #TNFSF14: The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. | ||
#TNFSF9: This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction. | #TNFSF9: This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction. | ||
#TNFSF15: The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. TNFSF15 is present prominently in the vasculature of normal ovary but diminishes in ovarian cancer as the disease progresses. Silencing TNFSF15 | #TNFSF15: The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. TNFSF15 is present prominently in the vasculature of normal ovary but diminishes in ovarian cancer as the disease progresses. Silencing TNFSF15 greatly facilitates angiogenesis and tumor growth, whereas systemic application of recombinant TNFSF15 inhibits angiogenesis and tumor growth. | ||
greatly facilitates angiogenesis and tumor growth, whereas systemic application of recombinant TNFSF15 inhibits angiogenesis and tumor growth. | |||
''sequence-specific DNA binding transcription factor activity'' | ''sequence-specific DNA binding transcription factor activity'' |
Revision as of 02:36, 2 February 2013
Project name | <html><img src="/images/9/94/Report.png" border="0" /></html> Main project page <html><img src="/images/c/c3/Resultset_previous.png" border="0" /></html>Previous entry<html> </html>Next entry<html><img src="/images/5/5c/Resultset_next.png" border="0" /></html> |
Gene Expression Round 2K562
phosphotransferase activity, alcohol group as acceptor
structural molecule activity
Protein Kinase Activity
structural molecule activity
structural molecule activity
anion transmembrane transporter activity
protein tyrosine kinase activity
kinase activity
SK-N-SH
signaling receptor activity
signal transducer activity
sequence-specific DNA binding
G-protein coupled receptor activity
sequence-specific DNA binding transcription factor activity
transmembrane transporter activity
growth factor activity
receptor binding
sequence-specific DNA binding transcription factor activity
transporter activity
|